1. BBLG extends rhNELL-1 product shelf life to 24 months. 2. Extension improves manufacturing efficiency and supply-chain flexibility. 3. CEO emphasizes operational milestones support long-term shareholder value. 4. rhNELL-1 is critical for targeted bone regeneration in challenging cases. 5. Company committed to ongoing clinical development and strategic partnerships.
FAQ
Why Bullish?
The extension of the shelf life is a positive development that indicates operational efficiency and readiness for commercialization, which typically boosts investor confidence and can lead to increased share value. Historical examples show that similar announcements in biotech have often resulted in stock price rallies, particularly when innovations improve prospects for product viability and marketability.
How important is it?
The announcement directly affects BBLG's manufacturing and commercialization strategy, signaling operational effectiveness that impacts investor perceptions. As companies in biotech often see significant stock reactions to product viability news, this shelf life extension is a considerable factor.
Why Short Term?
The immediate market response will likely gauge investor sentiment as BBLG advances its rhNELL-1. Positive benchmarks such as this could yield a quick rise in stock prices, especially if investors view this as a precursor to further successful developments.
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation, trading under the symbol BBLG on NASDAQ, has confirmed an extension of the shelf life for its rhNELL-1 product to 24 months. This announcement aligns with the Company's previously established forecasts and is backed by ongoing stability data. The achievement marks a significant milestone, following previous validations of 12- and 18-month shelf life.
Significance of Shelf Life Extension
The newly validated 24-month shelf life is expected to provide multiple operational benefits for Bone Biologics. These advantages include:
- Enhanced manufacturing efficiency: Longer shelf life reduces production frequency and improves resource allocation.
- Improved inventory management: By extending the product lifespan, the Company can better manage stock levels and reduce waste.
- Increased supply-chain flexibility: Longer shelf life allows for more dynamic distribution strategies and response to market demands.
- Clinical readiness: Ensures product availability during key clinical studies and commercialization phases.
Company Insights and Future Outlook
Jeff Frelick, Chief Executive Officer of Bone Biologics, commented on this development: “This milestone reflects continued execution against our development and manufacturing objectives. We believe extending the expected shelf life of rhNELL-1 to 24 months is an important step toward commercialization, improving manufacturing efficiency, supply-chain flexibility, and product readiness. As we advance rhNELL-1 through clinical development, these operational milestones are expected to support disciplined capital deployment and long-term shareholder value creation.”
About Bone Biologics
Founded to drive advancements in regenerative medicine for bone, Bone Biologics continues to innovate in the orthobiologic sector. The company is focusing on developing rhNELL-1 as a differentiated bone growth factor aimed at promoting controlled and targeted bone regeneration, particularly in challenging fusion environments. Bone Biologics retains rights for the use of its technology in trauma and osteoporosis applications.
For more information, visit www.bonebiologics.com.
Forward-Looking Statements
Certain statements in this release, including anticipated achievements for 2025 and the success of clinical studies involving rhNELL-1, are considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. These statements are subject to inherent uncertainties. Actual results may differ materially from those anticipated due to various factors, including market conditions and operational risks. Investors are encouraged to review the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and other filings with the SEC.
Contact Information
For investor inquiries, please contact:
CORE IR
Phone: (212) 655-0924
Email: investors@bonebiologics.com